Skip to main content

1 Result(s)

within Y.-I. Park Remove this filter Medicine & Public Health Remove this filter

and

  1. No Access

    Article

    Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer

    Background We evaluated the maximum tolerated dose (MTD) and safety of sunitinib plus capecitabine/cisplatin (XP) or capecitabine/oxaliplatin (XELOX) in Korean patients with advanced gast...

    K.-W. Lee, S. R. Park, D.-Y. Oh, Y.-I. Park, R. Khosravan… in Investigational New Drugs (2013)